Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857375 | PMC |
| http://dx.doi.org/10.4103/lungindia.lungindia_401_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Newer Therapies for Refractory Infection in Adults: A Systematic Review.
Antibiotics (Basel)
October 2024
Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
Background: () infection is a global health concern, affecting approximately two-thirds of the world's population. Standard first-line treatment regimens often fail, necessitating alternative rescue therapies.
Objectives: This review aims to evaluate the efficacy and safety of newer treatment regimens in patients who have failed initial eradication therapy.
Single-Arm, Prospective, Interventional Study of Eradication Rescue Therapy with Rifabutin, Metronidazole, and Vonoprazan.
J Clin Med
June 2024
Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
Rescue eradication can be challenging. Rifabutin (RBT) demonstrates high activity against and is incorporated into various rescue eradication regimens. This exploratory study was performed to evaluate the efficacy and safety of a rescue regimen comprising RBT, metronidazole (MNZ), and vonoprazan (VPZ).
View Article and Find Full Text PDFRespirable konjac glucomannan microparticles as antitubercular drug carriers: Effects of in vitro and in vivo interactions.
Int J Biol Macromol
September 2023
Centre for Marine Sciences (CCMAR), Universidade do Algarve, 8005-139 Faro, Portugal; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal. Electronic address:
Pulmonary delivery of drugs is potentially beneficial in the context of lung disease, maximising drug concentrations in the site of action. A recent work proposed spray-dried konjac glucomannan (KGM) microparticles as antitubercular drug (isoniazid and rifabutin) carriers to treat pulmonary tuberculosis. The present work explores in vitro and in vivo effects of these microparticles, focusing on the ability for macrophage uptake, the exhibited antibacterial activity and safety issues.
View Article and Find Full Text PDFDesign and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin.
Eur J Pharm Sci
August 2023
Nanobiofar Group, Department of Pharmacology, Pharmacy & Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela Campus Vida, 15782 Santiago de Compostela, Spain; Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela Campus Vida, 15782 Santiago de Compostela, Spain. Electronic address:
Tuberculosis (TB) is a life-threatening disease and a main cause of death worldwide. It mainly affects the lungs, and it is attributed to the infection with Mycobacterium tuberculosis (MTB). Current treatments consist of the oral administration of combinations of antibiotics including rifabutin, in high doses and for long periods of time.
View Article and Find Full Text PDFA Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers.
Clin Pharmacol Drug Dev
August 2023
BeiGene, Ltd. and BeiGene USA, Inc., San Mateo, California, USA.
Zanubrutinib is a second-generation Bruton tyrosine kinase inhibitor that is primarily metabolized by CYP3A enzymes. Previous drug-drug interaction (DDI) studies have demonstrated that co-administration of zanubrutinib with rifampin, a strong CYP3A inducer, reduces zanubrutinib plasma concentrations, potentially impacting activity. The impact of the co-administration of zanubrutinib with less potent CYP3A inducers is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!